ViiV HIV Drug Access Expanded: Licensing Deal for Long-Acting Treatment

GSK Expands HIV Drug Licensing to Include Treatment Regimens

GSK has broadened a three-year-old licensing agreement with the Medicines Patent Pool, a United Nations-backed organization, to allow generic manufacturers to produce its long-acting HIV medication, cabotegravir, for treatment purposes.Previously, the agreement focused solely on HIV prevention.

This expansion enables existing generic licensees to develop, manufacture, and distribute versions of cabotegravir for use in combination with Johnson & Johnson’s long-acting rilpivirine. This development follows updated guidance from the World health Organization,which now recommends this combination as a treatment option for HIV.